Aerovate Therapeutics Partners with Westwood & Wilshire to Place Senior Vice President of Clinical Development

This article was originally posted on Globe Newswire

WALTHAM, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE)- Sanjeev Khindri has joined Aerovate Therapeutics as Senior Vice President, Clinical Development. Dr. Khindri has more than 15 years of experience as a clinical trialist and leader across all stages of clinical development in respiratory medicine including experience in rare diseases such as PAH and Idiopathic Pulmonary Fibrosis as well as a strong understanding of pediatric drug development and orphan drug legislation. He previously led medical teams at Akari Pharmaceuticals plc, Actelion Ltd., Galecto Biotech AB, and GSK plc. He trained in adult internal medicine and clinical pharmacology in the United Kingdom.

The search was successfully led by Gerard Danishek.

About Aerovate Therapeutics, Inc.

Aerovate is a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Aerovate’s initial focus is on advancing AV-101, its proprietary dry powder inhaled formulation of the drug imatinib for the treatment of patients with PAH. Learn more at aerovatetx.com or follow the company on Twitter and LinkedIn.

About Westwood & Wilshire

Westwood & Wilshire is a retained executive-search firm delivering premier talent in life sciences, healthcare and advanced technology to the world’s most innovative companies. Our specialty is bringing top-flight senior leadership to growing venture-backed companies looking for the best people to fill their C-Suite hires. Clients around the globe work with Westwood & Wilshire to build world-changing companies. Contact information can be found at https://westwoodwilshire.com/contact-us.